Dear Colleagues, Dear Friends, Dear All,

In recent years, Gortec has experienced a strong dynamic in its therapeutic trials, some of which are unique, others innovative, and yet others strategic.

The biannual meetings of the Head&Neck intergroup provide opportunities to share progress and discuss new projects, with representation from professions involved in managing head and neck carcinomas.

The latest intergroup in late 2023 was also marked by the renewal of the board of directors, and I am honored to have been invited to assume the presidency. I thank all the voters and all the members of the board of directors for their trust. The current board of directors is now composed of the following members:

• President: Yoann Pointreau
• President Elect: Yungan Tao
• Vice-President: Christophe Le Tourneau
• Treasurer: Julian Biau
• Vice-Treasurer: Xu Shan Sun
• Secretary: Juliette Thariat
• Vice-Secretary: Pierre Blanchard
• As well as Pierre Boisselier, Florence Huguet, Anouchka Modesto, and Esma Saada.

Dr. Laurent Martin and Dr. Pierre Graff have left the board, and I thank them on behalf of the board for their contributions over the past years.

This change in the board is correlated with a reorganization of Gortec's organizational chart, with General Direction (CEO/CMO) as Prof. Jean Bourhis and General Direction assistance as Christelle Lopez, who previously held the position of Administrative and Financial Director.

The current organization of Gortec has allowed for the internalization of all functions, enabling the continued team dynamics and therapeutic trials.

Of course, we rely on all investigators and centers to effectively enroll patients in all our trials.

A big thank you to everyone.

Best Regards.